Allspring Global Investments Holdings LLC Purchases New Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Allspring Global Investments Holdings LLC purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 10,574 shares of the biotechnology company’s stock, valued at approximately $79,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $33,000. GAMMA Investing LLC lifted its stake in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares in the last quarter. Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $80,000. Syon Capital LLC purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $99,000. Finally, Oxford Asset Management LLP purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $99,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $8.76 on Friday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.02 and a fifty-two week high of $11.31. The firm has a 50 day moving average price of $10.08 and a 200 day moving average price of $8.65. The company has a market capitalization of $1.83 billion, a PE ratio of -33.69, a price-to-earnings-growth ratio of 2.50 and a beta of 1.04.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BCRX shares. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Bank of America raised their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price target for the company. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Finally, Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 28th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.